Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

Scher, Howard I.; Jia, Xiaoyu; Bono, Johann S. de; Fleisher, Martin; Pienta, Kenneth J.; Raghavan, Derek; Heller, Glenn

doi:10.1016/s1470-2045(08)70340-1

Cited by 575 publications

(486 citation statements)

References 23 publications

Supporting

Mentioning

466

Contrasting

Unclassified

Order By: Relevance

“…Association of detection of !5 traditional CellSearch isolated CTCs/7.5 mL with poor prognosis in patients with advanced prostate cancer was initially reported around a decade ago (27)(28)(29) and has been recently further validated in several large-scaled clinical trials (30)(31)(32)(33). In our small patient cohort, we observed the associations of…”

Section: Discussionsupporting

confidence: 51%

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

Mao

Guo

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: To develop an approach for the investigation of different subtypes of circulating tumor cells (CTC) and other cells to evaluate their potential prognostic value of prostate cancer.Experimental Design: Malignancy of CTCs undergoing epithelial-to-mesenchymal transition (EMT) was confirmed by repeated FISH. Subgroups of CTCs in 81 patients with prostate cancer (43 castration resistant and 38 untreated localized) were correlated to disease aggressiveness parameters. AUC analysis was applied to compare the performance for metastasis prediction between serum PSA level alone and a combined risk score using both PSA and EMTing CTC count. Circulating megakaryocytes and cancer patient survival association was performed using Cox model.Results 0).Conclusions: This CTC analysis approach and the potential association of megakaryocytes with cancer prognosis may greatly enhance our ability to investigate the cancer metastasis process and to predict/monitor cancer progression.

show abstract

Section: Discussionsupporting

confidence: 51%

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

Mao

Guo

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Assessment of CTC using CellSearch has been cleared by the Food and Drug Administration as a prognostic indicator, in conjunction with other clinical methods, for patients with metastatic breast, prostate, and colorectal cancers. Studies in metastatic breast, colorectal, and prostate cancer showed that patients about to start new lines of chemotherapy could be divided into groups with favourable and unfavourable prognosis on the basis of the number of CTCs measured with the analytically valid CellSearch system(Veridex, Raritan, NJ, USA) [3,[5][6][7][8][9][10][11][12][13]20]. When studying the association between the number of CTCs and evolution of the disease, researchers generally use a single cutpoint to identify favorable and unfavorable response groups, such as 5 CTCs for MBC [3,4,14], three for metastatic colorectal cancer [11], and five for castration resistant prostate cancer [7].…”

Section: Discussionmentioning

confidence: 99%

“…Circulating tumor cells (CTCs) have been shown to be an independent prognostic factor in metastatic breast cancer (MBC) [3][4][5][6], in metastatic prostate cancer [7][8][9][10] and in metastatic colorectal cancer [11,12]. They represent a promising tool for therapeutic monitoring: an elevated number of CTCs measured at any time in the clinical course were associated with a high likelihood of a very short time to progression.…”

Section: Introductionmentioning

confidence: 99%

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

Botteri

Sandri

Bagnardi

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Research and Treatment, Springer Verlag, 2009, 122 (1), pp.211-217. <10.1007/s10549-009-0668-7>. EPIDEMIOLOGYModeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer Abstract Circulating tumor cell (CTC) count has been shown to be an independent predictor of progression in metastatic breast, prostate, and colorectal cancer. A cutpoint is generally used to identify favorable and unfavorable response groups. In this study, we propose an approach in which the number of CTCs is analyzed as a continuous predictor, to detect the shape of the relationship between CTCs and prognosis of metastatic breast cancer. We evaluated the association of baseline CTC with progression-free survival (PFS) and overall survival (OS) in a series of 80 patients treated for advanced breast cancer at the European Institute of Oncology, Milan. The association between CTCs and prognosis was analyzed with standard categorical survival analysis and spline regression models. At baseline, median age was 55 years; 33 patients were newly diagnosed with metastatic breast cancer (41%), while 28 (35%) and 19 (24%) were pretreated with one and two previous chemotherapy lines, respectively. After a median follow-up of 28 months, 76 disease progressions and 44 deaths were observed. Kaplan-Meier curves showed a clear association between CTCs and PFS (P-value 0.03) and OS (Pvalue \ 0.01). Patients with no CTC at baseline had a significantly better prognosis. When analyzing the CTCs as a continuous variable, we found an increase in risk with increasing number of CTCs, for both PFS and OS. The increase rate lessened after approximately 5 CTCs. CTCs represent a robust prognostic factor in the metastatic breast cancer setting. A nonlinear increase in risk of both progression and death with increasing number of CTCs was observed, with a lessening increase after approximately 5 CTCs. If distinct prognostic groups are to be identified, women with no CTC could plausibly represent a distinct favorable one.

show abstract

“…surface-enhanced Raman spectroscopy biomarker | cancer cell identification | multiplexing | silver nanoparticles E arly and rapid identification of malignant cells [ideally freeflowing in biological fluids such as urine (1) or blood (2)(3)(4)] is a central goal in cancer research. Accordingly, seeking improvements in sensitivity and accuracy of detection and quantification through, for example, the development of cell-specific diagnostic tools and biomarkers is an active enterprise.…”

mentioning

confidence: 99%

Quantitative ratiometric discrimination between noncancerous and cancerous prostate cells based on neuropilin-1 overexpression

Pallaoro

Braun

Moskovits

2011

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

A multiplexed, ratiometric method is described that can confidently distinguish between cancerous and noncancerous epithelial prostate cells in vitro. The technique is based on bright surfaceenhanced resonance Raman scattering (SERRS) biotags (SBTs) infused with unique Raman reporter molecules, and carrying cellspecific peptides. Two sets of SBTs were used. One targets the neuropilin-1 (NRP-1) receptors of cancer cells through the RPARPAR peptide. The other functions as a positive control (PC) and binds to both noncancerous and cancer cells through the HIV-derived TAT peptide. Point-by-point 2D Raman maps of the spatial distribution of the two tags were constructed with subcellular resolution from cells simultaneously incubated with the two sets of SBTs. Averaging the SERRS signal over a given cell yielded an NRP/PC ratio from which a robust quantitative measure of the overexpression of the NRP-1 by the cancer cell line was extracted. The use of a local, on-cell reference produces quantitative, statistically robust measures of overexpression independent of such sources of uncertainty as variations in the location of the focal plane, the local cell concentration, and turbidity.surface-enhanced Raman spectroscopy biomarker | cancer cell identification | multiplexing | silver nanoparticles E arly and rapid identification of malignant cells [ideally freeflowing in biological fluids such as urine (1) or blood (2-4)] is a central goal in cancer research. Accordingly, seeking improvements in sensitivity and accuracy of detection and quantification through, for example, the development of cell-specific diagnostic tools and biomarkers is an active enterprise. Although it is known that such cells are present in body fluids, concentrating them to levels appropriate for confident identification and quantification is still a serious challenge, despite significant advances that have been made by, for example, using microfluidics (5). Once collected, the cells must be identified as either cancerous or noncancerous within tolerable confidence limits, which may be improved by, for example, using several nonredundant biomarkers. Numerous promising identification methods have been reported using antibodies. In this article, we report a technique based on surface-enhanced Raman spectroscopy (SERS) and biotags that produce bright surface-enhanced resonance Raman scattering (SERRS) signals, comparable to or exceeding the intensities of fluorescent tags. The SERRS biotags (SBTs) used in this study exploit peptides as recognition moieties. We show that using SBTs ratiometrically can provide highly statistically significant, quantitative measures of neuropilin-1 (NRP-1) overexpression insensitive to normal causes of uncertainty in optical measurements such as variations in focal plane, cell concentration, and turbidity.Normal Raman signals from cells and their infrared (FTIR) absorbance patterns have been previously used to differentiate between cancer and normal cells (6-9). SERS has been used as an alternative immunohistochemistry (IH...

show abstract

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

Abstract: SUMMARYBackground-To assess the use of circulating tumor cell (CTC) number as a continuous variable as a prognostic factor for survival, and for the clinical management of patients with progressive metastatic castration-resistant prostate cancer receiving first-line chemotherapy.

Cited by 575 publications

References 23 publications

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis

Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer

Quantitative ratiometric discrimination between noncancerous and cancerous prostate cells based on neuropilin-1 overexpression

Contact Info

Product

Resources

About